NeoTract Announces Expanded Coverage for UroLift System Treatment for Patients with Enlarged Prostate

Friday, Feb 15, 2019

NeoTract, a wholly owned subsidiary of Teleflex Incorporated focused on addressing unmet needs in the field of urology, today announced that Humana, one of the nation’s largest private health insurers, is now providing insurance coverage for the UroLift® System, a minimally invasive in-office treatment that provides rapid relief and recovery from the symptoms of benign prostatic hyperplasia (BPH).

Humana insures more than 9.2 million lives through their commercial and Medicare Advantage products. With more than 3.5 million Medicare Advantage members, Humana is also one of the country's largest administrators of Medicare Advantage plans.

NeoTract also announced that an additional 90,000 lives are now covered for the UroLift System by Motion Picture Industry Pension & Health Plans (MPI), which is administered by Anthem Blue Cross – This is an encouraging step forward as Anthem Blue Cross is the only independent licensee of the Blue Cross Blue Shield Association not currently allowing member access to the UroLift System procedure. With these recent coverage decisions, a large majority of insured men in America now have access to the UroLift System procedure using their health insurance benefits.

“These coverage decisions are a major testament to the clinical benefits of the UroLift System for treating Benign Prostatic Hyperplasia (BPH), a common condition that significantly impacts the overall health of men with symptomatic BPH as well as the quality of life for those men and their partners,” said Dave Amerson, president of Teleflex Interventional Urology business unit. “We are pleased to see the continued acceptance of the UroLift System as a standard-of-care therapy for patients with symptomatic BPH. This coverage milestone will expand lasting and durable symptom relief to millions of men, allowing them to return to a healthier and better quality of life.”

BPH, also known as enlarged prostate, is a common condition marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep, and decreased quality of life.BPH affects over 40 million men in the United States alone.If left untreated, the condition can worsen over time and cause permanent bladder damage.

The UroLift System is the only minimally invasive treatment option that has been shown to provide rapid and durable symptomatic and urinary flow rate improvement without causing sexual dysfunction.The Prostatic Urethral Lift procedure is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines.


Other News